160 related articles for article (PubMed ID: 15834297)
1. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).
Agabiti-Rosei E; Trimarco B; Muiesan ML; Reid J; Salvetti A; Tang R; Hennig M; Baurecht H; Parati G; Mancia G; Zanchetti A;
J Hypertens; 2005 May; 23(5):1091-8. PubMed ID: 15834297
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
Zanchetti A; Hennig M; Baurecht H; Tang R; Cuspidi C; Carugo S; Mancia G
J Hypertens; 2007 Dec; 25(12):2463-70. PubMed ID: 17984668
[TBL] [Abstract][Full Text] [Related]
3. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid J; Rodicio J; Safar M; Eckes L; Ravinetto R
J Hypertens; 1998 Jul; 16(7):949-61. PubMed ID: 9794735
[TBL] [Abstract][Full Text] [Related]
4. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
Zanchetti A; Bond MG; Hennig M; Tang R; Hollweck R; Mancia G; Eckes L; Micheli D;
J Hypertens; 2004 Jun; 22(6):1201-12. PubMed ID: 15167456
[TBL] [Abstract][Full Text] [Related]
5. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid JL; Rodicio J; Safar M; Eckes L; Rizzini P;
Circulation; 2002 Nov; 106(19):2422-7. PubMed ID: 12417537
[TBL] [Abstract][Full Text] [Related]
6. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study.
Paliotti R; Ciulla MM; Hennig M; Tang R; Bond MG; Mancia G; Magrini F; Zanchetti A
J Hypertens; 2005 Jun; 23(6):1203-9. PubMed ID: 15894896
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
[TBL] [Abstract][Full Text] [Related]
8. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA).
Giannattasio C; Failla M; Hennig M; Hollweck R; Laurent S; Mallion JM; Reid J; Safar M; Bond G; Zanchetti A; Mancia G
J Hypertens; 2005 Mar; 23(3):557-62. PubMed ID: 15716697
[TBL] [Abstract][Full Text] [Related]
9. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA).
Zanchetti A; Hennig M; Hollweck R; Bond G; Tang R; Cuspidi C; Parati G; Facchetti R; Mancia G
Circulation; 2009 Sep; 120(12):1084-90. PubMed ID: 19738145
[TBL] [Abstract][Full Text] [Related]
10. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.
Agabiti-Rosei E; Ambrosioni E; Dal Palù C; Muiesan ML; Zanchetti A
J Hypertens; 1995 Nov; 13(11):1325-34. PubMed ID: 8984131
[TBL] [Abstract][Full Text] [Related]
12. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
13. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
Mancia G; Facchetti R; Parati G; Zanchetti A
Circulation; 2012 Jul; 126(5):569-78. PubMed ID: 22761453
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).
Zanchetti A
J Hypertens Suppl; 1995 Dec; 13(4):S35-9. PubMed ID: 8824685
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atheroscelerosis (ELSA).
Zanchetti A
Blood Press Suppl; 1996; 4():30-5. PubMed ID: 8973780
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients.
Agabiti-Rosei E; Zulli R; Muiesan ML; Salvetti M; Rizzoni D; Corbellini C; Monteduro C
Blood Press; 1998 May; 7(3):160-9. PubMed ID: 9758086
[TBL] [Abstract][Full Text] [Related]
17. Lacidipine: a review of its use in the management of hypertension.
McCormack PL; Wagstaff AJ
Drugs; 2003; 63(21):2327-56. PubMed ID: 14524737
[TBL] [Abstract][Full Text] [Related]
18. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA).
Tang R; Hennig M; Thomasson B; Scherz R; Ravinetto R; Catalini R; Rubba P; Zanchetti A; Bond MG
J Hypertens; 2000 Feb; 18(2):197-201. PubMed ID: 10694188
[TBL] [Abstract][Full Text] [Related]
19. Changes in left ventricular geometry during antihypertensive treatment.
Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
[TBL] [Abstract][Full Text] [Related]
20. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
